Loading...

Bellerophon Therapeutics, Inc.

BLPH•NASDAQ
Healthcare
Biotechnology
$0.01
$-0.01(-36.84%)

Bellerophon Therapeutics, Inc. (BLPH) Stock Overview

Explore Bellerophon Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.8/100

Key Financials

Market Cap146.8K
P/E Ratio-0.01
EPS (TTM)$-0.89
ROE-1.64%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$0.06

BLPH Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Bellerophon Therapeutics, Inc. (BLPH) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.06.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.01 and a market capitalization of 146.8K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for BLPHStats details for BLPH are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for BLPHAnalyst Recommendations details for BLPH are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

CEO

Craig R. Jalbert CIRA

Employees

18

Headquarters

184 Liberty Corner Road, Warren, NJ

Founded

2015

Frequently Asked Questions

;